Literature DB >> 19820921

Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.

Alex Bogason1, Hasanuzzaman Bhuiyan, Michèle Masquelier, Christer Paul, Astrid Gruber, Sigurd Vitols.   

Abstract

AIMS: To study anthracycline-induced apoptosis in leukemic cells isolated from patients with acute myelogenous leukemia (AML) in vitro and to compare intracellular anthracycline concentrations causing apoptosis in vitro with those obtained in vivo during anthracycline treatment.
METHODS: Mononuclear blood cells from AML patients were isolated before (n = 20) and after anthracycline infusion (n = 24). The pre-treated cells were incubated in vitro with daunorubicin (DNR) and/or idarubicin (IDA). Anthracycline concentrations were determined by high-performance liquid chromatography, and apoptosis was detected by propidium iodine staining using a flow cytometer.
RESULTS: There was a clear concentration-response relationship between intracellular anthracycline levels and apoptosis albeit with a large interindividual variation. Intracellular levels >1200 muM always led to high apoptosis development (>60%) in vitro. The intracellular concentrations of DNR in vivo (n = 24) were more than tenfold lower than the concentrations needed to induce effective apoptosis in vitro, although a significant relation between in vivo concentrations and clinical remission was found. We also found a significant relation between apoptosis induction in leukemic cells by IDA in vitro and clinical remission.
CONCLUSIONS: Our results indicate that intracellular anthracycline levels in vivo are suboptimal and that protocols should be used that increase intracellular anthracycline levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820921     DOI: 10.1007/s00228-009-0734-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

1.  Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.

Authors:  P Staib; B Lathan; T Schinköthe; S Wiedenmann; B Pantke; T Dimski; D Voliotis; V Diehl
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

2.  Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.

Authors:  M Hunault-Berger; N Milpied; M Bernard; J P Jouet; M Delain; B Desablens; A Sadoun; F Guilhot; P Casassus; N Ifrah
Journal:  Leukemia       Date:  2001-06       Impact factor: 11.528

3.  Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.

Authors:  C Paul; J Liliemark; U Tidefelt; G Gahrton; C Peterson
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.

Authors:  D J Roovers; M van Vliet; A C Bloem; H M Lokhorst
Journal:  Leuk Res       Date:  1999-06       Impact factor: 3.156

6.  Doxorubicin-induced DNA degradation in murine thymocytes.

Authors:  G Zaleskis; E Berleth; S Verstovsek; M J Ehrke; E Mihich
Journal:  Mol Pharmacol       Date:  1994-11       Impact factor: 4.436

7.  Kinetics and sensitivity of daunorubicin in patients with acute leukemia.

Authors:  M W DeGregorio; W M Holleran; B A Macher; C A Linker; J R Wilbur
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 8.  Anthracycline and anthraquinone anticancer agents: current status and recent developments.

Authors:  J W Lown
Journal:  Pharmacol Ther       Date:  1993-11       Impact factor: 12.310

9.  Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.

Authors:  C Paul; U Tidefelt; J Liliemark; C Peterson
Journal:  Leuk Res       Date:  1989       Impact factor: 3.156

10.  Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.

Authors:  P Galettis; J Boutagy; D D Ma
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more
  4 in total

1.  Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.

Authors:  Alex Bogason; Angelica L Quartino; Pierre Lafolie; Michèle Masquelier; Mats O Karlsson; Christer Paul; Astrid Gruber; Sigurd Vitols
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

2.  Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.

Authors:  Kongfei Li; Chao Hu; Chen Mei; Zhigang Ren; Juan Carlos Vera; Zhengping Zhuang; Jie Jin; Hongyan Tong
Journal:  J Transl Med       Date:  2014-06-12       Impact factor: 5.531

3.  Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).

Authors:  Maria Omsland; Øystein Bruserud; Bjørn T Gjertsen; Vibeke Andresen
Journal:  Oncotarget       Date:  2017-01-31

Review 4.  Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review.

Authors:  Sijongesonke Peter; Sibusiso Alven; Rejoice Bethusile Maseko; Blessing Atim Aderibigbe
Journal:  Molecules       Date:  2022-07-13       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.